Long-Term Efficacy, Tolerability, and Renal Safety of Atazanavir/Ritonavir-based Antiretroviral Therapy in a Cohort of Treatment-Naïve Patients with HIV-1 Infection: the REMAIN Study

References

• Ray M, Logan R, Sterne JA, et al. The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. AIDS. 2010;24:123–137.
   PubMed Web of Science ®Google Scholar
• Sherer RD Jr, Fath MJ, Da Silva BA, Nicolau AM, Miller NL. The importance of potency and durability in HIV patient antiretroviral therapy preferences: A telephone survey. AIDS Patient Care STDs. 2005;19:794–802.10.1089/apc.2005.19.794
   PubMed Web of Science ®Google Scholar
• van Maarseveen N, Boucher C. Resistance to protease inhibitors. In: Geretti AM, ed. Antiretroviral resistance in clinical practice. London; 2006.
   Google Scholar
• Gupta R, Hill A, Sawyer AW, Pillay D. Emergence of drug resistance in HIV type 1–infected patients after receipt of first‐line highly active antiretroviral therapy: A systematic review of clinical trials. Clin Infect Dis. 2008;47:712–722.10.1086/592125
   PubMed Web of Science ®Google Scholar
• Panel on antiretroviral guidelines for adults and adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services; 2014. http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf. Accessed March 23, 2015.
   Google Scholar
• European AIDS Clinical Society. Guidelines: Version 7.1, November 2014. http://www.eacsociety.org/guidelines/eacs-guidelines/eacs-guidelines.html. Accessed March 23, 2015.
   Google Scholar
• Molina JM, Andrade-Villanueva J, Echevarria J, et al. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet. 2008;372:646–655.10.1016/S0140-6736(08)61081-8
   PubMed Web of Science ®Google Scholar
• Molina JM, Andrade-Villanueva J, Echevarria J, et al. Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study. J Acquir Immune Defic Syndr. 2010;53:323–332.10.1097/QAI.0b013e3181c990bf
   PubMed Web of Science ®Google Scholar
• Daar ES, Tierney C, Fischl MA, et al. Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1. Ann Intern Med. 2011;154:445–456.10.7326/0003-4819-154-7-201104050-00316
   PubMed Web of Science ®Google Scholar
• Elzi L, Marzolini C, Furrer H, et al. Treatment modification in human immunodeficiency virus–infected individuals starting combination antiretroviral therapy between 2005 and 2008. Arch Intern Med. 2010;170:57–65.10.1001/archinternmed.2009.432
   PubMed Web of Science ®Google Scholar
• Maggiolo F, Leone S, Cologni G, Valenti D, Quinzan G, Suter F. Persistence on first line HAART is influenced by dosing schedule. Abstracts of the 18th International AIDS Society World AIDS conference, July 18–23, 2010, Vienna, Austria.
   Google Scholar
• Abgrall S, Ingle SM, May MT, et al. Durability of first ART regimen and risk factors for modification, interruption or death in HIV-positive patients starting ART in Europe and North America 2002–2009. AIDS. 2013;27:803–813.
   PubMed Web of Science ®Google Scholar
• Wensing AM, Calvez V, Gunthard HF, et al. 2014 update of the drug resistance mutations in HIV-1. Top Antivir Med. 2014;22:642–650.
   PubMedGoogle Scholar
• DAIDS Regulatory Support Centre. Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events Version 1.0, December, 2004; Clarification August 2009. http://rsc.tech-res.com/Document/safetyandpharmacovigilance/Table_for_Grading_Severity_of_Adult_Pediatric_Adverse_Events.pdf. Accessed August 13, 2014.
   Google Scholar
• Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Ann Intern Med. 1999;130:461–470.10.7326/0003-4819-130-6-199903160-00002
   PubMed Web of Science ®Google Scholar
• National Research Council. The prevention and treatment of missing data in clinical trials. Panel on handling missing data in clinical trials. Committee on National Statistics, Division of Behavioral and Social Sciences and Education. Washington, DC: The National Academies Press; 2010.
   Google Scholar
• Rockstroh JK, DeJesus E, Henry K, et al. A randomized, double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus coformulated emtricitabine and tenofovir DF for initial treatment of HIV-1 infection: analysis of week 96 results. J Acquir Immune Defic Syndr. 2013;62:483–486.10.1097/QAI.0b013e318286415c
   PubMed Web of Science ®Google Scholar
• Jansen K, Sonnerborg A, Brockmeyer N, et al. Long-term efficacy and safety of atazanavir/ritonavir treatment in a real-life cohort of treatment-experienced patients with HIV type 1 infection. AIDS Res Hum Retroviruses. 2013;29:564–573.10.1089/aid.2012.0092
   PubMed Web of Science ®Google Scholar
• Svedhem-Johansson V, Pugliese P, Brockmeyer NH, et al. Long-term gender-based outcomes for atazanavir/ritonavir (ATV/r)- containing regimens in treatment experienced patients with HIV. Curr HIV Res. 2013;11:333–341.10.2174/1570162X113119990037
   PubMed Web of Science ®Google Scholar
• Zhang D, Chando TJ, Everett DW, Patten CJ, Dehal SS, Humphreys WG. In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation. Drug Metab Dispos. 2005;33:1729–1739.10.1124/dmd.105.005447
   PubMed Web of Science ®Google Scholar
• DeJesus E, Rockstroh JK, Henry K, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: A randomised, double-blind, phase 3, non-inferiority trial. Lancet. 2012;379:2429–2438.10.1016/S0140-6736(12)60918-0
   PubMed Web of Science ®Google Scholar
• Johnson M, Grinsztejn B, Rodriguez C, et al. 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures. AIDS. 2006;20:711–718.10.1097/01.aids.0000216371.76689.63
   PubMed Web of Science ®Google Scholar
• Landovitz R, Ribaudo H, Ofotokun I. Efficacy and tolerability of atazanavir, raltegravir, or darunavir with FTC, tenofovir: ACTG 5257 [Abstract 85]. 21st Conference on Retroviruses and Opportunistic Infections, March 3–6, 2014; Boston, MA, USA.
   Google Scholar
• Ribaudo HJ, Daar ES, Tierney C, et al. Impact of UGT1A1 Gilbert variant on discontinuation of ritonavir-boosted atazanavir in AIDS Clinical Trials Group Study A5202. J Infect Dis. 2013;207:420–425.10.1093/infdis/jis690
   PubMed Web of Science ®Google Scholar
• Uy J, Hu W, Wirtz V, et al. Clinical significance of hyperbilirubinemia in the CASTLE study. J Int AIDS Soc. 2010;13:P93.10.1186/1758-2652-13-S4-P93
   Google Scholar